Literature DB >> 17510302

Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport.

Thomas M Daly1, Carmen M Dumaual, Xin Miao, Mark W Farmen, Reuben K Njau, Dong-Jing Fu, Nancy L Bauer, Sandra Close, Nancy Watanabe, Carsten Bruckner, Paul Hardenbol, Richard D Hockett.   

Abstract

BACKGROUND: Drug metabolism is a multistep process by which the body disposes of xenobiotic agents such as therapeutic drugs. Genetic variation in the enzymes involved in this process can lead to variability in a patient's response to medication.
METHODS: We used molecular-inversion probe technology to develop a multiplex genotyping assay that can simultaneously test for 1227 genetic variants in 169 genes involved in drug metabolism, excretion, and transport. Within this larger set of variants, we performed analytical validation of a clinically defined core set of 165 variants in 27 genes to assess accuracy, imprecision, and dynamic range.
RESULTS: In a test set of 91 samples, genotyping accuracy for the core set probes was 99.8% for called genotypes, with a 1.2% no-call (NC) rate. The majority of the core set probes (133 of 165) had < or = 1 genotyping failure in the test set; a subset of 12 probes was responsible for the majority of failures (mainly NC). Genotyping results were reproducible upon repeat testing with overall within- and between-run variation of 1.1% and 1.4%, respectively-again, primarily NCs in a subset of probes. The assay showed stable genotyping results over a 6-fold range of input DNA.
CONCLUSIONS: This assay generates a comprehensive assessment of a patient's metabolic genotype and is a tool that can provide a more thorough understanding of patient-to-patient variability in pharmacokinetic responses to drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510302     DOI: 10.1373/clinchem.2007.086348

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  18 in total

Review 1.  Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact.

Authors:  Federico M Goodsaid; Shashi Amur; Jiri Aubrecht; Michael E Burczynski; Kevin Carl; Jennifer Catalano; Rosane Charlab; Sandra Close; Catherine Cornu-Artis; Laurent Essioux; Albert J Fornace; Lois Hinman; Huixiao Hong; Ian Hunt; David Jacobson-Kram; Ansar Jawaid; David Laurie; Lawrence Lesko; Heng-Hong Li; Klaus Lindpaintner; James Mayne; Peter Morrow; Marisa Papaluca-Amati; Timothy W Robison; John Roth; Ina Schuppe-Koistinen; Leming Shi; Olivia Spleiss; Weida Tong; Sharada L Truter; Jacky Vonderscher; Agnes Westelinck; Li Zhang; Issam Zineh
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

2.  Concordance of DMET plus genotyping results with those of orthogonal genotyping methods.

Authors:  C A Fernandez; C Smith; W Yang; R Lorier; K R Crews; N Kornegay; J K Hicks; C F Stewart; J D Kawedia; L B Ramsey; C Liu; W E Evans; M V Relling; U Broeckel
Journal:  Clin Pharmacol Ther       Date:  2012-08-08       Impact factor: 6.875

3.  Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.

Authors:  Hersh Sagreiya; Hersh Sagrieya; Caroline Berube; Alice Wen; Ramesh Ramakrishnan; Alain Mir; Amy Hamilton; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-07       Impact factor: 2.089

4.  Pharmacogenetics and personal genomes.

Authors:  Michael J Wagner
Journal:  Per Med       Date:  2009-11-01       Impact factor: 2.512

5.  Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.

Authors:  Y Wang; B P Yan; D Liew; V W Y Lee
Journal:  Pharmacogenomics J       Date:  2017-01-24       Impact factor: 3.550

6.  Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.

Authors:  Kaavya Narasimhalu; Yoong Kwei Ang; Doreen Su Yin Tan; Deidre Anne De Silva; Kelvin Bryan Tan
Journal:  Clin Drug Investig       Date:  2020-11       Impact factor: 2.859

7.  Apple juice greatly reduces systemic exposure to atenolol.

Authors:  Hyewon Jeon; In-Jin Jang; SeungHwan Lee; Kyoichi Ohashi; Tsutomu Kotegawa; Ichiro Ieiri; Joo-Youn Cho; Seo Hyun Yoon; Sang-Goo Shin; Kyung-Sang Yu; Kyoung Soo Lim
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

8.  CYP4F2 genetic variant alters required warfarin dose.

Authors:  Michael D Caldwell; Tarif Awad; Julie A Johnson; Brian F Gage; Mat Falkowski; Paul Gardina; Jason Hubbard; Yaron Turpaz; Taimour Y Langaee; Charles Eby; Cristi R King; Amy Brower; John R Schmelzer; Ingrid Glurich; Humberto J Vidaillet; Steven H Yale; Kai Qi Zhang; Richard L Berg; James K Burmester
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

9.  Genotyping performance between saliva and blood-derived genomic DNAs on the DMET array: a comparison.

Authors:  Yueshan Hu; Erik A Ehli; Kelly Nelson; Krista Bohlen; Christophina Lynch; Patty Huizenga; Julie Kittlelsrud; Timothy J Soundy; Gareth E Davies
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240

10.  Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.

Authors:  Christoph Varenhorst; Stefan James; David Erlinge; John T Brandt; Oscar O Braun; Michael Man; Agneta Siegbahn; Joseph Walker; Lars Wallentin; Kenneth J Winters; Sandra L Close
Journal:  Eur Heart J       Date:  2009-05-09       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.